|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
FOXD1 and FOXD2 were more highly expressed in prostate cancer and lymph node metastases.
|
19220249 |
2009 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FOXD1 and FOXD2 were more highly expressed in prostate cancer and lymph node metastases.
|
19220249 |
2009 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FOXD1 and FOXD2 were more highly expressed in prostate cancer and lymph node metastases.
|
19220249 |
2009 |
|
Clear cell sarcoma of kidney
|
0.010 |
Biomarker
|
disease |
BEFREE |
FOXD1 which identifies cells giving rise to stromal elements, and CITED1, a marker for cells primed for nephrogenic epithelial differentiation, were both highly expressed in CCSK.
|
24488803 |
2014 |
|
Hodgkin Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we screened six Hodgkin lymphoma (HL) cell lines for FOX gene activity by comparative microarray profiling, revealing overexpression of FOXC1 and FOXD1, and reduced transcription of FOXN3, FOXO1, and FOXP1.
|
25043849 |
2014 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we screened six Hodgkin lymphoma (HL) cell lines for FOX gene activity by comparative microarray profiling, revealing overexpression of FOXC1 and FOXD1, and reduced transcription of FOXN3, FOXO1, and FOXP1.
|
25043849 |
2014 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we screened six Hodgkin lymphoma (HL) cell lines for FOX gene activity by comparative microarray profiling, revealing overexpression of FOXC1 and FOXD1, and reduced transcription of FOXN3, FOXO1, and FOXP1.
|
25043849 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.
|
25550559 |
2015 |
|
Diphtheria
|
0.010 |
Biomarker
|
disease |
BEFREE |
We crossed mice expressing Cre-recombinase under the FoxD1 promoter to Rosa26-loxP-STOP-loxP-iDTR mice and generated a bitransgenic line (FoxD1-Cre;Rs26-iDTR) in which FoxD1-derived cells heritably express simian or human diphtheria toxin receptor and are sensitive to DT.
|
27779900 |
2017 |
|
Pneumonia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Low-dose DT reduced lung PDGFRβ<sup>+</sup> stromal cells in the FoxD1-Cre;iDTR transgenic model without a differential effect on lung inflammation in DT-sensitive and DT-insensitive animals.
|
27779900 |
2017 |
|
Oropharyngeal disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
We delivered low-dose (0.5 ng/g) and high-dose (1ng/g × 2) to FoxD1-Cre;Rs26-iDTR mice and littermate control mice by oropharyngeal aspiration and evaluated ablation by flow cytometry and immunohistochemistry.
|
27779900 |
2017 |
|
Pneumonitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Low-dose DT reduced lung PDGFRβ<sup>+</sup> stromal cells in the FoxD1-Cre;iDTR transgenic model without a differential effect on lung inflammation in DT-sensitive and DT-insensitive animals.
|
27779900 |
2017 |
|
Glioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We examined the expression and function of Forkhead box D1 (FOXD1) in glioma cell behavior and found that FOXD1 was upregulated and directly correlated with the glioma grade.
|
28075458 |
2017 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that FOXD1 may serve as a novel regulator of glioblastoma cell behavior that may offer a novel target for gene targeted glioma therapies.
|
28075458 |
2017 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that FOXD1 may serve as a novel regulator of glioblastoma cell behavior that may offer a novel target for gene targeted glioma therapies.
|
28075458 |
2017 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that FOXD1 may serve as a novel regulator of glioblastoma cell behavior that may offer a novel target for gene targeted glioma therapies.
|
28075458 |
2017 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that FOXD1 may serve as a novel regulator of glioblastoma cell behavior that may offer a novel target for gene targeted glioma therapies.
|
28075458 |
2017 |
|
Ureteral obstruction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of Klf15 in Foxd1-expressing cells (Foxd1-Cre Klf15fl/fl) increased extracellular matrix deposition and myofibroblast proliferation as compared to wildtype (Foxd1-Cre Klf15+/+) mice after three and seven days of ureteral obstruction.
|
28651950 |
2017 |
|
Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inactivation of MAP3K7 in FOXD1-expressing cells results in loss of mesangial PDGFRΒ and juvenile kidney scarring.
|
29667914 |
2018 |
|
Glioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of FOXD1 is observed in glioma, lung cancer and breast cancer.
|
29864920 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, both our data and TCGA data found that high expression of FOXD1 predicted poor prognosis of CRC patients.
|
29864920 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Our clinical data indicated that high FOXD1 level was associated with tumor size (≥5 cm) and TNM tumor stage (III + IV).
|
29864920 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer.
|
29864920 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of FOXD1 is observed in glioma, lung cancer and breast cancer.
|
29864920 |
2018 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of FOXD1 is observed in glioma, lung cancer and breast cancer.
|
29864920 |
2018 |